Polatuzumab vedotin
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-POLATUZUMAB-VEDOTIN |
|---|---|
| Type | Drug |
| Aliases | PolivyПолатузумаб ведотин |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-DLBCL-NOS |
| Sources | SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | Anti-CD79b antibody-drug conjugate (MMAE payload) |
|---|---|
| Mechanism | CD79b-targeted IgG1 monoclonal antibody conjugated via cleavable protease-cleavable linker to monomethyl auristatin E (MMAE), a microtubule-disrupting payload. Internalized into CD79b+ B-cells, cleaves intracellularly, releases MMAE → mitotic arrest + apoptosis. |
| Typical dosing | 1.8 mg/kg IV day 1 of 21-day cycle (Pola-R-CHP, 6 cycles for newly-diagnosed DLBCL) |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
Replaces vincristine in Pola-R-CHP regimen for newly-diagnosed DLBCL with IPI ≥2 (POLARIX trial — improved PFS vs R-CHOP). Substantial cost + access constraint in Ukraine: NOT НСЗУ-reimbursed as of 2026-04-25 — funding pathway must be confirmed BEFORE plan finalization (clinical trial / charitable scheme / out-of-pocket). Premedication: antihistamine + paracetamol for first dose (infusion-related reactions). Hold for Grade ≥2 peripheral neuropathy.
Used By
Regimens
REG-POLA-R-BENDAMUSTINE- Polatuzumab vedotin + Rituximab + Bendamustine (Pola-BR), 6 cyclesREG-POLA-R-CHP- Polatuzumab vedotin + Rituximab + CHP (Pola-R-CHP), 6 cycles + 2× rituximab